British journal of pharmacology · 2026
Sevoflurane protects against testicular ischaemia-reperfusion injury in rats.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jiaxue, Yan Zhibing, Wei Shichao, Xiao Junshen, Wang Qifeng, Cao Hangxue, Hu Zhaoyang
Аннотация
BACKGROUND AND PURPOSE: Testicular torsion, a urological emergency, can lead to testicular dysfunction or infertility due to ischaemia-reperfusion injury, yet current interventions remain limited. Although sevoflurane, an inhaled anaesthetic, has shown organ-protective effects against ischaemia-reperfusion injury in the heart and brain, its role in testicular ischaemia-reperfusion injury is unclear.
EXPERIMENTAL APPROACH: A rat model of acute (720° with 3-h ischaemia/3-h reperfusion) and long-term (720° with 1-h ischaemia/3-day reperfusion) testicular ischaemia-reperfusion injury was set up to explore the protective effects and mechanisms of preconditioning and post-conditioning with sevoflurane.
KEY RESULTS: 1.5 minimum alveolar concentration (MAC) sevoflurane for 30 min significantly mitigated acute ischaemia-reperfusion injury, as shown by reductions in bilateral testicular oedema, oxidative stress (lower MDA levels), inflammation (decreased TNF-α, IL-6) and apoptosis (reduced Bax/Bcl-2 ratio). Long-term, it alleviated testicular atrophy and enhanced sperm count, motility and spermatogenesis. Mechanistically, sevoflurane activated ERK1/2 phosphorylation in the RISK pathway, with its protective effects being abolished by the ERK1/2 inhibitor U0126.
CONCLUSION AND IMPLICATIONS: Sevoflurane exerts acute and chronic protective effects against bilateral testicular ischaemia-reperfusion injury via ERK1/2 signalling and offers a novel pharmacological strategy to mitigate complications following de-torsion.
EXPERIMENTAL APPROACH: A rat model of acute (720° with 3-h ischaemia/3-h reperfusion) and long-term (720° with 1-h ischaemia/3-day reperfusion) testicular ischaemia-reperfusion injury was set up to explore the protective effects and mechanisms of preconditioning and post-conditioning with sevoflurane.
KEY RESULTS: 1.5 minimum alveolar concentration (MAC) sevoflurane for 30 min significantly mitigated acute ischaemia-reperfusion injury, as shown by reductions in bilateral testicular oedema, oxidative stress (lower MDA levels), inflammation (decreased TNF-α, IL-6) and apoptosis (reduced Bax/Bcl-2 ratio). Long-term, it alleviated testicular atrophy and enhanced sperm count, motility and spermatogenesis. Mechanistically, sevoflurane activated ERK1/2 phosphorylation in the RISK pathway, with its protective effects being abolished by the ERK1/2 inhibitor U0126.
CONCLUSION AND IMPLICATIONS: Sevoflurane exerts acute and chronic protective effects against bilateral testicular ischaemia-reperfusion injury via ERK1/2 signalling and offers a novel pharmacological strategy to mitigate complications following de-torsion.